Parenteral Drugs (India) (NSE:PDPL) Accounts Payable: ₹97.98 Mil (As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Accounts Payable?

Parenteral Drugs (India) NSE:PDPL 4 Accounts Payable is ₹97.98 Mil as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s Accounts Payable for the quarter that ended in Mar. 2022 was ₹97.98 Mil.

Parenteral Drugs (India)'s quarterly Accounts Payable declined from Sep. 2021 (₹80.36 Mil) to Dec. 2021 (₹0.00 Mil) but then increased from Dec. 2021 (₹0.00 Mil) to Mar. 2022 (₹97.98 Mil).

Parenteral Drugs (India)'s annual Accounts Payable declined from Mar. 2020 (₹79.31 Mil) to Mar. 2021 (₹78.13 Mil) but then increased from Mar. 2021 (₹78.13 Mil) to Mar. 2022 (₹97.98 Mil).

Parenteral Drugs (India) Accounts Payable Related Terms

Parenteral Drugs (India) Accounts Payable Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Accounts Payable Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 511.96 118.72 79.31 78.13 97.98

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.13 0.00 80.36 0.00 97.98
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹97.98 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Accounts Payable of ₹97.98 Mil as of Mar. 2022. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Accounts Payable too high?
Parenteral Drugs (India)'s current Accounts Payable is ₹97.98 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Accounts Payable compare to ZTS and CTLT?
Parenteral Drugs (India)'s Accounts Payable of ₹97.98 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Accounts Payable is ₹97.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Accounts Payable of ₹97.98 Mil. The current Accounts Payable is ₹97.98 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Accounts Payable is ₹97.98 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price